Plain-English translation of NCT06906341 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called relacorilant combined with chemotherapy to treat gynecological cancers—including ovarian, fallopian tube, peritoneal, and endometrial cancers. Depending on your cancer type and history, you would receive the medication by mouth along with chemotherapy infusions. The researchers want to see if this combination is safe and effective at slowing or stopping cancer growth.
Some patients with gynecological cancers have limited treatment options, especially after their cancer stops responding to standard chemotherapy or other drugs. This trial is exploring whether this medication, which works differently than traditional treatments, can help when added to existing chemotherapy drugs.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly over multiple 28-day treatment cycles. You would take the new medication by mouth for several days around each chemotherapy infusion, and receive chemotherapy drugs through an IV on specific days each cycle. Depending on which arm of the study you're in, you may also receive a third medication by IV every two weeks. You would continue treatment as long as the cancer isn't growing and you're not experiencing unmanageable side effects, with regular check-ins to monitor your health and how you're responding.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
United States